Yokohama University of Pharmacy · Department of Kampo Pharmacy · 准教授

Research keywords●和漢薬の新規薬効探索・●膵臓癌悪性化機構の解析・●ヘリコバクターハイルマニイ感染による胃MALTリンパ腫発症機構の解析・●膵臓癌新規治療薬の探索・和漢薬・膵臓癌・胃MALTリンパ腫・ヘリコバクター・ハイルマンニイ・病態生理学

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• 2. Yoshida H, Takahashi T , Nakamura M, Øverby A, Takahashi T, Ubukata K, Matsui H. A highly susceptible CD46 transgenic mouse model of subcutaneous infection with Streptococcus dysgalactiae subspecies equisimilis. J Infect Chemother. 2016; 22: 229-34.2016
• 6. Nakamura M, Takahashi T , Matsui H, Takahashi S, Murayama SY, Suzuki H, Tsuchimoto K. New Pharmaceutical Treatment of Gastric MALT Lymphoma: Anti-angiogenesis Treatment using VEGF Receptor Antibodies and Celecoxib. Curr Pharm Des. 2014; 20: 1097-103.2014
• 4. Nakamura M, Takahashi T , Matsui H, Baniwa Y, Takahashi S, Murayama SY, et al. Alteration of angiogenesis in Helicobacter heilmannii-induced mucosa-associated lymphoid tissue lymphoma: Interaction with c-Met and hepatocyte growth factor. J Gastroenterol Hepatol. 2014; 29 Suppl 4:70–6.2014
• 5. Matsui H, Takahashi T , Murayama SY, Uchiyama I, Yamaguchi K, Shigenobu S, et al. Development of New PCR Primers by Comparative Genomics for the Detection of Helicobacter suis in Gastric Biopsy Specimens. Helicobacter 2014; 19: 260-271.2014

• 膵臓がん転移予防薬の標的因子の同定と漢方薬の効果
• 前立腺幹細胞抗原（PSCA）を分子標的とする膵臓癌の創薬基盤の構築
• 胃マルトリンパ腫におけるヘリコバクター属の感染実態および分子標的薬の効果の解析
• マルトリンパ腫幹細胞ニッチと微小循環系の関連の解析

• Official profile